Unpacking the Potential of HER3-Targeted Therapy in NSCLC

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:

• Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
• The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
• The HER2xHER3 bispecific antibody zenocutuzumab
• The HER3-targeted antibody–drug conjugate SHR-A2009 

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supported by an educational grant from Daiichi Sankyo, Inc. 

Link to full program, including a downloadable highlights slideset: 
https://bit.ly/48ecElW

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.